Evommune licenses autoimmune drug in deal worth up to $1.1bn

Evommune licensed ex-China rights to Hinova’s experimental autoimmune drug EVO570 for $30m upfront and up to $1.1bn in milestones. It plans a mid-stage rheumatoid arthritis study in 2027.